Free Trial

4D Molecular Therapeutics (FDMT) SEC Filings & 10K Form

4D Molecular Therapeutics logo
$6.31 +0.53 (+9.17%)
(As of 12/20/2024 05:31 PM ET)

Recent 4D Molecular Therapeutics SEC Filings

DateFilerForm TypeView
12/11/2024
3:15 PM
4D Molecular Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/15/2024
4:05 PM
4D Molecular Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13G/A
11/14/2024
4:46 PM
4D Molecular Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13G/A
11/14/2024
2:15 PM
4D Molecular Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
Form SC 13G/A
11/14/2024
8:13 AM
4D Molecular Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
Form SC 13G/A
11/13/2024
3:33 PM
4D Molecular Therapeutics (Issuer)
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2024
3:17 PM
4D Molecular Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
3:08 PM
4D Molecular Therapeutics (Subject)
BIOTECHNOLOGY VALUE FUND L P (Filed by)
Form SC 13G/A
11/12/2024
11:12 AM
4D Molecular Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
11/08/2024
1:17 PM
4D Molecular Therapeutics (Subject)
BlackRock, Inc. (Filed by)
Form SC 13G/A
11/06/2024
5:07 PM
4D Molecular Therapeutics (Subject)
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Form SC 13G
11/04/2024
9:55 AM
4D Molecular Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G
10/21/2024
3:11 PM
4D Molecular Therapeutics (Subject)
BlackRock, Inc. (Filed by)
Form SC 13G/A
09/18/2024
4:46 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2024
3:06 PM
4D Molecular Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/23/2024
5:04 AM
4D Molecular Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/18/2024
7:22 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
5:04 AM
4D Molecular Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/15/2024
5:13 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/12/2024
4:46 PM
4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2024
4:17 PM
4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/03/2024
4:11 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2024
3:43 PM
4D Molecular Therapeutics (Subject)
Bizily Scott (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2024
4:07 PM
4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2024
3:44 PM
4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
Form 144/A
06/24/2024
4:39 PM
4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/07/2024
4:04 PM
4D Molecular Therapeutics (Filer)
Form 424B5
06/07/2024
4:07 PM
4D Molecular Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/23/2024
7:45 PM
4D Molecular Therapeutics (Issuer)
Tomasello Shawn (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2024
6:10 PM
4D Molecular Therapeutics (Issuer)
GRAY SUSANNAH (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2024
6:11 PM
4D Molecular Therapeutics (Issuer)
MILLIGAN JOHN F (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2024
6:12 PM
4D Molecular Therapeutics (Issuer)
Miller-Rich Nancy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2024
6:16 PM
4D Molecular Therapeutics (Issuer)
THEUER CHARLES (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2024
6:17 PM
4D Molecular Therapeutics (Issuer)
Chacko Jacob (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
7:35 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2024
3:22 PM
4D Molecular Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/09/2024
3:09 PM
4D Molecular Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/18/2024
7:48 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2024
3:05 PM
4D Molecular Therapeutics (Filer)
Form DEF 14A
04/10/2024
3:06 PM
4D Molecular Therapeutics (Filer)
Form DEFA14A
04/10/2024
3:07 PM
4D Molecular Therapeutics (Filer)
Form ARS
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]
04/03/2024
6:18 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/29/2024
3:52 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/20/2024
3:40 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:01 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
4:15 PM
4D Molecular Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/21/2024
4:41 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2024
7:51 PM
4D Molecular Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
Form SC 13G/A
02/14/2024
8:56 AM
4D Molecular Therapeutics (Subject)
BIOTECHNOLOGY VALUE FUND L P (Filed by)
Form SC 13G/A
02/14/2024
7:43 AM
4D Molecular Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
Form SC 13G/A
02/13/2024
9:56 AM
4D Molecular Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
Form SC 13G/A
02/12/2024
8:04 PM
4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2024
7:22 PM
4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/08/2024
3:50 PM
4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/07/2024
7:32 PM
4D Molecular Therapeutics (Issuer)
Kim Robert Young (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2024
6:42 PM
4D Molecular Therapeutics (Issuer)
Kim Robert Young (Reporting)
Form 3/A
02/05/2024
4:27 PM
4D Molecular Therapeutics (Filer)
Form 424B5
02/05/2024
3:35 PM
4D Molecular Therapeutics (Filer)
Form S-3ASR
01/25/2024
3:59 PM
4D Molecular Therapeutics (Subject)
BlackRock Inc. (Filed by)
Form SC 13G/A
01/23/2024
3:50 PM
4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2024
3:15 PM
4D Molecular Therapeutics (Subject)
VIKING GLOBAL INVESTORS LP (Filed by)
Form SC 13G/A
01/08/2024
3:19 PM
4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
4:44 PM
4D Molecular Therapeutics (Issuer)
HALVORSEN OLE ANDREAS (Reporting)
Ott David C. (Reporting)
Shabet Rose Sharon (Reporting)
VIKING GLOBAL INVESTORS LP (Reporting)
Viking Global Opportunities GP LLC (Reporting)
Viking Global Opportunities Illiquid Investments Sub-Master LP (Reporting)
Viking Global Opportunities Parent GP LLC (Reporting)
Viking Global Opportunities Portfolio GP LLC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
3:49 PM
4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
4:48 PM
4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
7:30 AM
4D Molecular Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:FDMT) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners